BR112018016367A2 - anticorpo anti-cd20 canino quimérico - Google Patents

anticorpo anti-cd20 canino quimérico

Info

Publication number
BR112018016367A2
BR112018016367A2 BR112018016367A BR112018016367A BR112018016367A2 BR 112018016367 A2 BR112018016367 A2 BR 112018016367A2 BR 112018016367 A BR112018016367 A BR 112018016367A BR 112018016367 A BR112018016367 A BR 112018016367A BR 112018016367 A2 BR112018016367 A2 BR 112018016367A2
Authority
BR
Brazil
Prior art keywords
antibody
canine anti
chimeric canine
chimeric
canine
Prior art date
Application number
BR112018016367A
Other languages
English (en)
Inventor
David Pancook James
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of BR112018016367A2 publication Critical patent/BR112018016367A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se a anticorpos anti-cd20 quiméricos caninizados para a proteína canina cd20 e métodos de uso para tratar certos transtornos tais como linfoma de célula b não hodgkin em cães.
BR112018016367A 2016-02-18 2017-02-10 anticorpo anti-cd20 canino quimérico BR112018016367A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296729P 2016-02-18 2016-02-18
PCT/US2017/017337 WO2017142800A1 (en) 2016-02-18 2017-02-10 Chimeric canine anti-cd20 antibody

Publications (1)

Publication Number Publication Date
BR112018016367A2 true BR112018016367A2 (pt) 2019-01-22

Family

ID=58098709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016367A BR112018016367A2 (pt) 2016-02-18 2017-02-10 anticorpo anti-cd20 canino quimérico

Country Status (14)

Country Link
US (4) US10519244B2 (pt)
EP (1) EP3416984B1 (pt)
JP (1) JP6661019B2 (pt)
KR (1) KR102131544B1 (pt)
CN (1) CN108699152B (pt)
AU (1) AU2017219596B2 (pt)
BR (1) BR112018016367A2 (pt)
CA (1) CA3014461C (pt)
DK (1) DK3416984T3 (pt)
EA (1) EA039434B1 (pt)
ES (1) ES2868650T3 (pt)
MX (2) MX2018009955A (pt)
NZ (1) NZ744192A (pt)
WO (1) WO2017142800A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102131544B1 (ko) 2016-02-18 2020-07-07 엘랑코 유에스 인코포레이티드 키메라 개 항-cd20 항체
US12297272B2 (en) * 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
JP2021059499A (ja) 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
JP2024526122A (ja) * 2021-06-17 2024-07-17 ペットメディックス・リミテッド 抗イヌｃｄ２０抗体
WO2023010057A1 (en) * 2021-07-28 2023-02-02 Atreca, Inc. Atrc-101 target expression assay
GB202217993D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
WO2025121944A1 (ko) * 2023-12-08 2025-06-12 주식회사 박셀바이오 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
JP4745242B2 (ja) * 2003-05-20 2011-08-10 アプライド モレキュラー エボリューション，インコーポレイテッド Ｃｄ２０結合分子
US9228008B2 (en) * 2004-05-28 2016-01-05 Idexx Laboratories, Inc. Canine anti-CD20 antibodies
WO2009086072A2 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
WO2011109108A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
WO2013054127A1 (en) * 2011-10-13 2013-04-18 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
EP3174901B1 (en) * 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
KR102131544B1 (ko) * 2016-02-18 2020-07-07 엘랑코 유에스 인코포레이티드 키메라 개 항-cd20 항체

Also Published As

Publication number Publication date
US10519244B2 (en) 2019-12-31
CN108699152A (zh) 2018-10-23
KR102131544B1 (ko) 2020-07-07
KR20180096804A (ko) 2018-08-29
JP6661019B2 (ja) 2020-03-11
JP2019507128A (ja) 2019-03-14
ES2868650T3 (es) 2021-10-21
DK3416984T3 (da) 2021-04-26
CN108699152B (zh) 2022-08-19
EP3416984A1 (en) 2018-12-26
US20210163618A1 (en) 2021-06-03
EA201891499A1 (ru) 2019-01-31
US12195548B2 (en) 2025-01-14
US20190194342A1 (en) 2019-06-27
US10941206B2 (en) 2021-03-09
MX2018009955A (es) 2018-11-29
EP3416984B1 (en) 2021-03-31
US20230257476A1 (en) 2023-08-17
NZ744192A (en) 2019-11-29
CA3014461A1 (en) 2017-08-24
WO2017142800A1 (en) 2017-08-24
US20200131273A1 (en) 2020-04-30
EA039434B1 (ru) 2022-01-27
CA3014461C (en) 2023-02-28
AU2017219596B2 (en) 2019-07-04
AU2017219596A1 (en) 2018-07-19
MX2022014375A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112018016367A2 (pt) anticorpo anti-cd20 canino quimérico
CY1123236T1 (el) Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3
CY2024032I2 (el) Χιμαιρικοι υποδοχεις αντιγονου που βασιζονται σε αντισωματα μονου τομεα και μεθοδοι χρησης αυτων
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
ECSP17080639A (es) Moléculas de unión a lag-3 y métodos de uso de las mismas
IL250831A0 (en) Antibodies and chimeric antigen receptors specific for cd19, compositions containing same and uses thereof
ECSP18006831A (es) Moléculas de unión a pd-1 y métodos de uso de las mismas
BR112017017927A2 (pt) receptores quiméricos de antígenos anti-dll3 e métodos de uso
LT3223845T (lt) Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
IL253166B (en) Bispecific antibodies against cd3 and cd20
EP3186279C0 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
PL3599251T3 (pl) Konstrukcja chimerycznego receptora antygenowego ukierunkowanego na antygen cd20 i identyfikacja aktywności zmodyfikowanych w ten sposób limfocytów t
IL265219A (en) Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
SA517381663B1 (ar) أجسام مضادة تستهدف مولد ضد نضج لخلايا وطرق استخدامها b
PT2948477T (pt) Constructos de anticorpo para cdh19 e cd3
PE20231655A1 (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
NZ721309A (en) Anti-cd3 antibodies and methods of use
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2017000985A (es) Anticuerpos anti-pd-1.
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
EP3507303C0 (en) CD20 ANTIBODY

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]